Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan;31(1):1-5.
doi: 10.1097/CAD.0000000000000818.

Biological effects of verbascoside and its anti-inflammatory activity on oral mucositis: a review of the literature

Olga Nigro  1 , Alessandro Tuzi, Tiziana Tartaro, Alice Giaquinto, Ilaria Vallini, Graziella Pinotti
Affiliations
Review

Biological effects of verbascoside and its anti-inflammatory activity on oral mucositis: a review of the literature

Olga Nigro et al. Anticancer Drugs. 2020 Jan.

Abstract

Oral mucositis is among the most common tissue toxicities associated with both cytotoxic cancer regimens and head and neck radiotherapy. Current management of oral mucositis might comprise growth factors and cytokines, anti-inflammatory agents, anesthetics, analgesics, antimicrobial and coating agents, cryotherapy and mucosal protectants. Despite its long history and its impact on patients, there are currently no effective options for the prevention or treatment of mucositis. In recent years, more attention has been focused on the role of natural drugs. Verbascoside belongs to the phenylpropanoid glycosides family. Several biological properties have been described, such as anti-inflammatory, antimicrobial, antitumor and antioxidant. Verbascoside, particularly when in solution with polyvinylpyrrolidone and sodium hyaluronate, thanks to barrier effect, is useful in re-epithelialization and in reducing pain, oral mucositis score, burning and erythema.

PubMed Disclaimer

References

    1. Sonis ST. Oral mucositis in head and neck cancer: risk, biology, and management. 2013, American Society of Clinical Oncology Educational Book/ASCO American Society of Clinical Oncology Meeting
    1. Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, et al.; Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014; 120:1453–1461
    1. Elting LS, Keefe DM, Sonis ST, Garden AS, Spijkervet FK, Barasch A, et al.; Burden of Illness Head and Neck Writing Committee. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer. 2008; 113:2704–2713
    1. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al.; Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004; 100:1995–2025
    1. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004; 4:277–284

MeSH terms

LinkOut - more resources